Skip to content
MedsAcross

Medicine

Cathflo Activase 2.2 mg/2 mL powder for injection

Alteplase · Intravenous · Genentech
Available on requestPrescription onlyUS FDA

Cathflo Activase 2.2 mg/2 mL powder for injection is a prescription medicine containing Alteplase for intravenous use, marketed by Genentech, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Storage as on the product label

Key facts

Active ingredient (INN)
Alteplase
Brand
Cathflo Activase
Strength
2.2 mg/2 mL
Dosage form
Powder for injection
Route
Intravenous
Packs
10 vials, 1 vial
Marketing authorisation holder
Genentech
Manufacturer
Genentech
Origin register
US FDA, United States
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
B01AD02 Alteplase
HS code (indicative)
3002.15Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
4 September 2001
Identifiers
DailyMed set ID 91ecdef2-95ff-42dd-a31c-c8a09cab3ad9NDC 50242-041Application BLA103172

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
10 vial in 1 carton / 2 mL in 1 vial50242-041-10Genentech14 October 2019
1 vial in 1 carton / 2 mL in 1 vial50242-041-64Genentech4 September 2001

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 13 November 1987Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Alteplase

Clinical summary

Alteplase is a prescription medicine indicated for the treatment of acute Ischemic Stroke (AIS), among other approved uses. It is available as kits and powder for injection for intravenous use. MedsAcross supplies Alteplase for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Alteplase

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Cathflo Activase 2.2 mg/2 mL powder for injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.